<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences

Find me on:

Recent Posts

Cancer, CLIA & Precision Medicine | High-Quality Testing

Posted by MD Biosciences on Dec 2, 2015 3:31:26 PM

As an already fully functioning good laboratory practices (GLP) operation, MD Biosciences has recently achieved a new stage of value through CLIA certification for our high quality-testing services in the clinical and diagnostic arenas. CLIA or the Clinical Laboratory Improvements Amendments was put in place at the federal level to ensure a high level of laboratory testing. Therefore, clients can be assured that MD Biosciences meets these high quality standards and feel confident that their samples will be handled with the utmost technical and professional care to obtain reliable results.

Read More

Topics: Personalized medicine, precision medicine, CLIA, Certification, High-quality

Targeting Microbiomes & Biomarkers: Inflammation World Congress

Posted by MD Biosciences on Aug 20, 2015 4:30:00 PM


The 12th World Congress on Inflammation wrapped up on Wednesday August 12th after four days packed with cutting edge inflammatory research by key opinions leaders in the field. Presentations hit every aspect of the scientific spectrum from development of pre-clinical models through retrospective studies on new target therapies and everything in between. Highlights of the conference included the Keynote Lecture by Luke O’Neill of Trinity College Dublin, the Symposium “Mechanisms Underlying Microbiome-Mediated Inflammation”, and multiple discussions on identifying and targeting novel biomarkers of inflammatory diseases.

Read More

Topics: Inflammation, metabolic, Preclinical Discovery, Microbiome, Biomarkers, World Congress on Inflammation

Pain-related Characteristics | MIA-induced Preclinical OA Model

Posted by MD Biosciences on Mar 9, 2012 11:06:00 AM

Osteoarthritis (OA) is a widespread condition that affects greater than 70% of the elderly population and poses a heavy cost burden on healthcare. It is a chronic degenerative disease characterized byt the loss of articular cartilage components, which affects the entire joint structure. One of the major complaints by OA patients is the loss of joint function as well as chronic pain. Current therapies are focused on alleviating joint pain, however full pain relief is rarely experienced and significant side affects are commonly present. Research is not only focused disease pathology but also on understanding the mechanisms responsible for induction and maintenance of pain states.

Read More

Topics: Pain

Choosing DNCB or FITC-induced Contact Hypersensitivity Models

Posted by MD Biosciences on Jun 1, 2011 10:37:00 AM

Read More

Topics: Dermal, Inflammation